Thyrocare Technologies Q4 FY26: Revenue up 20% YoY

Thyrocare Technologies posts strong FY26 growth

Thyrocare Technologies Ltd., a Navi Mumbai-based diagnostic and preventive care testing company, reported a steady FY26 performance marked by faster revenue growth, improving margins, and higher testing volumes. The company operates in pathology and preventive testing, and has built a wide distribution footprint through healthcare centres and franchise-led collection.

The latest reported numbers show double-digit year-on-year (YoY) growth in quarterly revenue, along with a sharp improvement in profitability in select quarters. Investors also tracked shareholder-friendly actions, as the board declared an interim dividend and approved a bonus issue proposal during FY26.

Q4FY26 and FY26 headline revenue numbers

For Q4FY26, Thyrocare reported consolidated revenue from operations of Rs 223.95 crore, up 20% YoY from Rs 187.16 crore in Q4FY25. On a full-year basis, FY26 consolidated revenue from operations was Rs 829.04 crore, up 21% YoY compared with Rs 687.35 crore in FY25.

Separately, a quarterly results table (all figures in crore) showed Net Sales of Rs 210.67 crore in Mar 2026, compared with Rs 173.87 crore in Mar 2025. Another consolidated quarterly series showed revenue at Rs 224 crore in Mar 2026 and Rs 187 crore in Mar 2025, broadly aligning with the Q4 trend.

Profitability: operating profit, EBITDA and margins

Operating performance improved alongside revenue. In the quarterly results table (crore), Operating Profit rose to Rs 72.63 crore in Mar 2026 from Rs 55.64 crore in Mar 2025. Profit After Tax (PAT) in the same table stood at Rs 43.58 crore in Mar 2026, up from Rs 21.95 crore in Mar 2025.

A consolidated quarterly table also reported Operating Profit of Rs 75 crore in Mar 2026 (with OPM at 34%) versus Rs 57 crore in Mar 2025 (with OPM at 30%). In Q2FY26, the company reported EBITDA of Rs 75.36 crore, up 49% YoY, with an EBITDA margin of 33%. For Q1FY26, reported highlights showed EBITDA of Rs 57.46 crore with an EBITDA margin of 30%.

On margins, the text also cited improvement in gross margin, including a statement that gross margin rose 100 bps YoY to 72.3% in a reported period, and another reference that gross margins improved by 113 basis points YoY.

Q1FY26 and Q2FY26: PAT growth and margins

Thyrocare’s FY26 quarters saw strong YoY profit growth in its reported highlights. In Q1FY26, revenue from operations was Rs 193.03 crore versus Rs 156.91 crore in Q1FY25 (a 23% rise). PAT in Q1FY26 was reported at Rs 38.06 crore versus Rs 23.47 crore (a 62% rise), with a PAT margin of 20%.

In Q2FY26, the company reported consolidated revenue of Rs 216.53 crore (up 22% YoY) and PAT of Rs 47.90 crore (up 82% YoY), with a PAT margin of 22%.

The provided data also included another quarterly block stating Net Profit of Rs 38.93 crore and Profit Before Tax of Rs 50.48 crore for a quarter, highlighting that multiple disclosures and tables were referenced in the material.

Segment mix: franchise, partnership and D2C contribution

The revenue mix described in the text remains franchise-led. Franchisee contribution was stated at about 61%, while the partnership segment contributed about 34%, and D2C was about 5%.

Within the pathology business, the material noted that franchise revenue grew 12% YoY, while partnership revenue including PharmEasy business grew 39% YoY. Consolidated revenue growth of 18% YoY was also referenced, driven primarily by a 20% increase in the Pathology segment in the cited period.

Network scale, franchise count and testing volumes

Thyrocare is described as a leading diagnostic and preventive care testing company in India, established in 1995. The company was said to have a network of more than 1 lakh healthcare centres across the country.

Operational scale featured prominently in the provided text. It referred to 40 labs in India, and a franchisee count of 10,800. On volumes, the company processed 49.6 million tests in Q3FY26, marking 22% YoY growth. Another reference put processed investigations at 6 crore 59 million (65.9 million) in the context provided.

Interim dividend and proposed 2:1 bonus issue

During the Q2FY26 result announcement, the board declared an interim dividend of Rs 7 per equity share (face value Rs 10, pre-bonus). The record date was 24-October-2025.

The board also approved a bonus issue in the ratio of 2:1, subject to statutory, regulatory, and shareholder approvals. Such actions were part of the information investors tracked alongside quarterly performance.

Stock snapshot: share price and market capitalisation

As per the provided data, Thyrocare Tech.’s current share price was stated as Rs 545.25. The company’s market capitalisation was stated as Rs 8,678.488800375 crore, calculated based on the latest share price.

Key reported quarterly financials (crore)

Market impact: what investors focused on

The market discussion in the supplied text pointed to improving profitability and a stronger margin trajectory as key factors behind investor attention. In the consolidated quarterly series, operating margin moved up to 34% in Mar 2026, compared with 30% in Mar 2025, indicating better operating leverage.

Operational indicators also mattered because diagnostics is a volume-led business. The reported 49.6 million tests processed in Q3FY26 and the stated mix between franchise, partnership, and D2C offered a lens on how demand and channel strategy are shaping revenue.

The material also referenced stock performance context, including that the stock was up 35% from 2025 lows, down 11% from 2025 highs, and delivered 50% plus returns over one year (as stated).

Analysis: why FY26 numbers matter for Thyrocare

FY26 results, as provided, highlight two themes. First is consistent double-digit revenue growth across quarters and the full year, supported by pathology-led momentum. Second is profitability improvement, visible through higher operating profits and reported EBITDA growth in Q2FY26.

The segment detail is important because it shows a heavy reliance on the franchise model (about 61%) while partnership revenue is growing faster in the cited period. The company’s disclosures also suggest management is conscious of the growth base, with an expectation stated in the material of mid to high teens growth over the next three years.

Conclusion

Thyrocare’s FY26 updates point to higher revenue, stronger profitability in key quarters, and expanding test volumes, alongside shareholder actions such as an interim dividend and a proposed 2:1 bonus issue. The next set of quarterly disclosures and any updates on the bonus issue approvals will remain key milestones to track.